Cited by 574Atrial Fibrillation Management and OutcomesHeart Failure Treatment and ManagementCardiac Health and Mental Health

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction

Open access

Olsson, Lars G., Swedberg, Karl, Ducharme, Anique, Granger, Christopher B., Michelson, Eric L., McMurray, John J.V., Puu, Margareta, Yusuf, Salim, Pfeffer, Marc A.·2006·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2006.01.060

Open this paper in CoChat — free account

Abstract

Objectives We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF) and a broad range of ejection fractions (EFs).Background Atrial fibrillation is associated with an increased risk of adverse CV outcomes in patients with CHF and reduced EF. The risk of AF in patients with CHF and preserved left ventricular ejection fraction (PEF) is unknown.Methods A total of 7,599 patients with symptomatic CHF were randomized to candesartan or placebo. Patients were divided by baseline EF (< or =40% or >40%) in low or preserved EF groups. Major outcomes were cardiovascular death or hospitalization for worsening heart failure, and all-cause mortality. Median follow-up was 37.7 months.Results A total of 670 (17%) patients in the low EF group and 478 (19%) in the PEF group had AF at baseline. Atrial fibrillation predicted a high risk of cardiovascular morbidity and mortality regardless of baseline EF. Patients with AF and low EF had the highest absolute risk for adverse CV outcomes. However, AF was associated with greater relative increased risk of the major outcomes in patients with PEF than in patients with low EF: hazard ratio 1.72 (95% confidence interval [CI] 1.45 to 2.06) versus 1.29 (95% CI 1.14 to 1.46), respectively. The same was true for the risk of all-cause mortality. Candesartan was associated with similar treatment effects regardless of baseline rhythm.Conclusions Atrial fibrillation is associated with an increased risk of CV outcomes in patients with CHF and either reduced EF or PEF. Candesartan improved outcomes similarly regardless of baseline rhythm.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2006.01.060

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study
Wang, T. J., Larson, M. G., Levy, D., Vasan, R. S., Leip, E. P., Wolf, P. A., D’Agostino, R. B., Murabito, J. M., Kannel, W. B., & Benjamin, E. J. (2003) · Circulation · doi:10.1161/01.cir.0000072767.89944.6e · Cited by 1,970
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment
Michel Komajda, N. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00700-5 · Cited by 1,219
Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy
Maisel, W. H., & Stevenson, L. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03373-8 · Cited by 972
Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials
Dries, D. L., Exner, D., Gersh, B., DOMANSKI, M. J., Waclawiw, M. A., & Stevenson, L. W. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00297-6 · Cited by 967
Heart failure with preserved left ventricular systolic function
Hogg, K. J., Swedberg, K. B., & McMurray, J. J. V. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.046 · Cited by 927
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826
Epidemiology of heart failure
Kannel, W. B., & Belanger, A. J. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90225-7 · Cited by 795
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women
Tsang, T. S. M., Gersh, B. J., Appleton, C. P., Tajik, A. J., Barnes, M. E., Bailey, K. R., Oh, J. K., Leibson, C. L., Montgomery, S. C., & Seward, J. B. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02373-2 · Cited by 652
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET
Swedberg, K., Olsson, L. G., Charlesworth, A., Cleland, J., Hanrath, P., Komajda, M., Metra, M., Torp-Pedersen, C., & Poole-Wilson, P. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi166 · Cited by 647
Hemodynamic Effects of an Irregular Sequence of Ventricular Cycle Lengths During Atrial Fibrillation
Clark, D. M., Plumb, V. J., Epstein, A. E., & Kay, G. N. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00254-4 · Cited by 610
Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients.
Middlekauff, H. R., Stevenson, W. G., & Stevenson, L. W. (1991) · Circulation · doi:10.1161/01.cir.84.1.40 · Cited by 576
Gender, age, and heart failure with preserved left ventricular systolic function
Masoudi, F. A., Havranek, E. P., Smith, G. L., Fish, R. H., Steiner, J. F., Ordin, D. L., & Krumholz, H. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02696-7 · Cited by 423
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
Maggioni, A. P., Latini, R., Carson, P. E., Singh, S. N., Barlera, S., Glazer, R. D., Masson, S., Cerè, E., Tognoni, G., & Cohn, J. N. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.033 · Cited by 406
Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey
Lenzen, M. J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.06.006 · Cited by 369
Effect of an irregular ventricular rhythm on cardiac output
Daoud, E. G., Weiss, R., Bahu, M., Knight, B. P., Bogun, F. M., Goyal, R., Harvey, M. N., Strickberger, S. A., Man, K. C., & Morady, F. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89297-1 · Cited by 361
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
Ducharme, A., Swedberg, K., Pfeffer, M. A., Cohen-Solal, A., Granger, C. B., Maggioni, A. P., Michelson, E. L., McMurray, J. J. V., Olsson, L., Rouleau, J. L., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.036 · Cited by 352
Outcomes in heart failure patients with preserved ejection fraction
Smith, G. L., Masoudi, F. A., Vaccarino, V., Radford, M. J., & Krumholz, H. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00185-2 · Cited by 333
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
Carson, P. E., Johnson, G. R., Dunkman, W. B., Fletcher, R. D., Farrell, L., & Cohn, J. N. (1993) · PubMed · Cited by 319
Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design
Swedberg, K. B., Pfeffer, M. A., Granger, C. B., Held, P., McMurray, J. J. V., Ohlin, G., Olofsson, B., Östergren, J., & Yusuf, S. (1999) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(99)90013-1 · Cited by 294
Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?
Khand, A. U., Rankin, A. C., Martin, W., Taylor, J., Gemmell, I., & Cleland, J. G. F. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.020 · Cited by 271
Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients
Solomon, S. D., Wang, D., Finn, P. V., Skali, H., Zornoff, L. A. M., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000144474.65922.aa · Cited by 267
Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure
Crijns, H. J. G. M. (2000) · European Heart Journal · doi:10.1053/euhj.1999.2107 · Cited by 259
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation
Wachtell, K., Hornestam, B., Lehto, M., Slotwiner, D. J., Gerdts, E., Olsen, M. H., Aurup, P., Dahlöf, B., Ibsen, H., Julius, S., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.080 · Cited by 244
Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors
Philbin, E. F., Rocco, T. A., Lindenmuth, N. W., Ulrich, K., & Jenkins, P. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00601-x · Cited by 238
Improving survival for patients with advanced heart failure: A study of 737 consecutive patients
Stevenson, W. G., Stevenson, L. W., Middlekauff, H. R., Fonarow, G. C., Hamilton, M. A., Woo, M. A., Saxon, L. A., Natterson, P. D., Steimle, A. E., Walden, J. A., et al. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00341-x · Cited by 220
The influence of atrial fibrillation on prognosis in mild to moderate heart failure : the V-HeFT studies
Carson, P. E., Johnson, G. R., Dunkman, W. B., Fletcher, R. D., Farrell, L., & Cohn, J. N. (1993) · Circulation · Cited by 157
Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function
Gustafsson, F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00845-x · Cited by 154
Atrial Fibrillation in Heart Failure
Stevenson, W. G., & Stevenson, L. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411209 · Cited by 141
Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure
Mathew, J., Hunsberger, S., Fleg, J. L., Sherry, F. M., Williford, W. O., & Yusuf, S. (2000) · CHEST Journal · doi:10.1378/chest.118.4.914 · Cited by 139
Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure
Mahoney, P. D., Kimmel, S., DeNofrio, D., Wahl, P. M., & Loh, E. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00144-7 · Cited by 133
Impact of Atrial Fibrillation on Mortality and Readmission in oLder Adults Hospitalized with Heart Failure
Ahmed, A., Thornton, P. L., Perry, G. J., Allman, R. M., & DeLong, J. F. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2003.11.011 · Cited by 60
Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure.
Tarantini, L., Faggiano, P. M., Senni, M., Lucci, D., Bertoli, D., Porcu, M., Opasich, C., Tavazzi, L., & Maggioni, A. P. (2002) · PubMed · Cited by 46
Effects of candesartan on mortality and morbidity in patients with chronic heart failure
Pfeffer, M., Swedberg, K. B., Granger, C. B., Held, P. H., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., Yusuf, S., & Pocock, S. (2003) · Cited by 30
Cardiovascular Morbidity and Mortality in Hypertensive Patients With a History of Atrial Fibrillation
Wachtell, K., Hornestam, B., & Lehto, M. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.05.065 · Cited by 8

Flagged first, then by citations

Sorted by citations

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
“with LV dysfunction and in hypertensive patients with LV hypertrophy.(219,236,237,239,246,250,686) Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.”
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gelder, I. C. V., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., Potter, T. J. R. D., Dwight, J., Guasti, L., Hanke, T., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae176 · Cited by 3,594
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A. M., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 3,072

See all 574

Authors: Olsson, L. G., Swedberg, K., Ducharme, A., Granger, C. B., Michelson, E. L., McMurray, J. J. V., Puu, M., Yusuf, S., & Pfeffer, M. A.
Affiliations: Sahlgrenska University Hospital (SE)
Montreal Heart Institute (CA)
Duke Medical Center (US)
AstraZeneca (United States) (US)
Western Infirmary (GB)
AstraZeneca (Sweden) (SE)
Brigham and Women's Hospital (US)
Corresponding author: Swedberg, Karl
ORCID: Swedberg, Karl
Ducharme, Anique
Granger, Christopher B.
McMurray, John J.V.
Yusuf, Salim
Pfeffer, Marc A.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2006-05
Volume: 47
Issue: 10
Pages: 1997-2004
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2006.01.060
OpenAlex: W104425974
Cited by: 574
References: 35
Citations by year: 2026: 17 · 2025: 25 · 2024: 26 · 2023: 17 · 2022: 18 · 2021: 37 · 2020: 33 · 2019: 24 · 2018: 22 · 2017: 39 · 2016: 37 · 2015: 32 · 2014: 25 · 2013: 44 · 2012: 29
FWCI: 23.22
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2670 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords: atrial fibrillation, chronic heart failure, left ventricular systolic dysfunction, preserved ejection fraction, candesartan, cardiovascular mortality, hospitalization for worsening heart failure, all-cause mortality, CHARM trial, angiotensin receptor blockers
MeSH terms: Aged, Atrial Fibrillation, Benzimidazoles, Biphenyl Compounds, Cardiovascular Diseases, Chronic Disease, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Prognosis, Risk, Stroke Volume, Tetrazoles, Ventricular Dysfunction, Left, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks